China Cord Blood Corp., of Hong Kong, said its board of directors has received a non-binding proposal letter from Golden Meditech Holdings Ltd. proposing to acquire all of the outstanding ordinary shares of the company not already directly or indirectly owned by Golden Meditech for $6.40 per share in cash. Read More
BOSTON – Shorter timelines to market and larger patient pools serve as major incentives for companies to bring clinical development work to China and India, although regulatory and cultural differences remain a hurdle. In its 24th year, the Partnerships in Clinical Trials conference started Wednesday. Read More
Having banked $38 million in a series A round late last year, cancer immunotherapy firm Potenza Therapeutics Inc. is "in good shape in terms of financing," thanks also to an undisclosed amount of new money from a deal with Astellas Pharma Inc., CEO Daniel Hicklin told BioWorld Asia. Read More
HONG KONG – A new patent law could help China step up enforcement and improve protections for intellectual property while giving biotech companies, both multinational and domestic, greater assurances that their products will be protected. Read More
HONG KONG – A study by researchers at the Duke-National University of Singapore Graduate Medical School (Duke-NUS) has identified a new means by which brown adipose tissue is regulated in the body, which offers an attractive new target for the development of new obesity treatments. Read More
SHANGHAI – Uni-Bio Science Group Ltd. has submitted a new drug application (NDA) to the CFDA for Uni-PTH, a biosimilar of Forteo (teriparatide, Eli Lilly and Co.). The Hong Kong-listed firm is planning for Uni-PTH – a parathyroid hormone 1-34 analogue to treat postmenopausal women with osteoporosis – to be on the market in Mainland China by 2017 at the earliest. Read More
Resverlogix Corp. CEO Donald McCaffrey told BioWorld Asia he is "very confident" about collecting the potential $400 million-plus from a licensing deal in China, Hong Kong, Taiwan and Macau with Shenzhen Hepalink Pharmaceutical Co. Ltd., centered on RVX-208, a late-stage, first-in-class, small-molecule BET bromodomain inhibitor. "We downplayed the number," he said. Read More
